000306672 001__ 306672
000306672 005__ 20251202115946.0
000306672 0247_ $$2doi$$a10.1002/cam4.71431
000306672 0247_ $$2pmid$$apmid:41317095
000306672 0247_ $$2pmc$$apmc:PMC12664089
000306672 037__ $$aDKFZ-2025-02665
000306672 041__ $$aEnglish
000306672 082__ $$a610
000306672 1001_ $$00000-0001-7600-7143$$aZitricky, Frantisek$$b0
000306672 245__ $$aSecond Primary Lung Cancer Associated With Family History of Lung Cancer.
000306672 260__ $$aHoboken, NJ$$bWiley$$c2025
000306672 3367_ $$2DRIVER$$aarticle
000306672 3367_ $$2DataCite$$aOutput Types/Journal article
000306672 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764600554_815119
000306672 3367_ $$2BibTeX$$aARTICLE
000306672 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000306672 3367_ $$00$$2EndNote$$aJournal Article
000306672 500__ $$a#LA:C020# Z999
000306672 520__ $$aFamilial clustering of initial primary lung cancer (IPLC) may be related to shared smoking habits, other environmental exposures and hereditary factors, but whether familial risk also influences the risk of second primary LC (SPLC) is not well known. We aimed to carry out a family study between first-degree relatives on SPLCs in Sweden.Population data on Swedish family relationships and the diagnosed cancers were obtained from the national registers from 1961 to 2021. IPLC was diagnosed in 54,429 patients of whom 534 were diagnosed with SPLC. Familial risk was assessed through the standardized incidence ratio (SIR with 95% confidence interval) adjusted for several potential confounders, including sex, age, calendar period, educational level and geographic region. Familial risks were analyzed by type of proband, histology and sex. In addition, we estimated the effect of family history on the cumulative proportion of patients developing SPLC by sex and histology.The estimated SIR for SPLC was 3.98 in patients without family history and 5.24 among those with a history of lung cancer in first-degree relatives. The SIR values depended on the histology of IPLC and of SPLC, with the highest SIRs for concordant histologies. For the adenocarcinoma-adenocarcinoma sequence, SIR estimates were 5.60 and 7.51 for non-familial and familial patients, respectively. The familial risks were further modulated by sex and type of affected relative, with the highest SIR for females with affected mothers (9.14).The results showed a positive association of family history of LC with risk of SPLC on top of high risk for SPLC in non-familial patients. The risks differed by sex, histology and type of affected relative. The data on family history of LC should alert about surveillance for SPLC and may be used in future risk stratification when eligibility for population screening is considered.
000306672 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000306672 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000306672 650_7 $$2Other$$aadenocarcinoma
000306672 650_7 $$2Other$$aincidence trend
000306672 650_7 $$2Other$$aproband
000306672 650_7 $$2Other$$asibling risk
000306672 650_2 $$2MeSH$$aHumans
000306672 650_2 $$2MeSH$$aLung Neoplasms: epidemiology
000306672 650_2 $$2MeSH$$aLung Neoplasms: genetics
000306672 650_2 $$2MeSH$$aLung Neoplasms: pathology
000306672 650_2 $$2MeSH$$aFemale
000306672 650_2 $$2MeSH$$aMale
000306672 650_2 $$2MeSH$$aSweden: epidemiology
000306672 650_2 $$2MeSH$$aMiddle Aged
000306672 650_2 $$2MeSH$$aAged
000306672 650_2 $$2MeSH$$aNeoplasms, Second Primary: epidemiology
000306672 650_2 $$2MeSH$$aNeoplasms, Second Primary: genetics
000306672 650_2 $$2MeSH$$aRegistries
000306672 650_2 $$2MeSH$$aRisk Factors
000306672 650_2 $$2MeSH$$aIncidence
000306672 650_2 $$2MeSH$$aGenetic Predisposition to Disease
000306672 650_2 $$2MeSH$$aAdult
000306672 650_2 $$2MeSH$$aAged, 80 and over
000306672 7001_ $$aSundquist, Kristina$$b1
000306672 7001_ $$aSundquist, Jan$$b2
000306672 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b3$$udkfz
000306672 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b4
000306672 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b5$$eLast author$$udkfz
000306672 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.71431$$gVol. 14, no. 23, p. e71431$$n23$$pe71431$$tCancer medicine$$v14$$x2045-7634$$y2025
000306672 909CO $$ooai:inrepo02.dkfz.de:306672$$pVDB
000306672 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000306672 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000306672 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000306672 9141_ $$y2025
000306672 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-07$$wger
000306672 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2022$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:04:21Z
000306672 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:04:21Z
000306672 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:04:21Z
000306672 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-08T17:04:21Z
000306672 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000306672 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000306672 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000306672 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000306672 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000306672 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x2
000306672 980__ $$ajournal
000306672 980__ $$aVDB
000306672 980__ $$aI:(DE-He78)B062-20160331
000306672 980__ $$aI:(DE-He78)HD01-20160331
000306672 980__ $$aI:(DE-He78)C020-20160331
000306672 980__ $$aUNRESTRICTED